Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results
Date:8/5/2011

ated in the ongoing extension portion of Study 203.
  • Results from the completed 28-day main portion of the study showing, at the highest lesinurad dose tested, the number of patients taking the combination who achieved the target sUA level of below 6 mg/dL was more than three times the number of patients who achieved the target on allopurinol alone. This translated into an overall response rate of 87 percent using a "last observation carried forward", or LOCF, analysis. The combination of lesinurad and allopurinol was generally well tolerated in the 28-day main portion of Study 203.
  • Results from a completed preclinical study showing that lesinurad is an active inhibitor of the OAT4 transporter, a uric acid transporter in the kidney believed to be responsible for the hyperuricemia caused by the anti-hypertensive diuretic agent, hydrochlorothiazide.  As hypertension is a common co-morbid condition in gout patients, this secondary lesinurad activity may benefit gout patients taking this common treatment for hypertension. Consistent with these preclinical results, a high level of response was observed with lesinurad in the subset of patients receiving thiazide diuretics in Study 203.
  • In June 2011, we presented data from a completed, multi-center, Phase 1, monotherapy, dose-escalation study of BAY-86-9766 (RDEA119) in advanced cancer patients at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.  BAY 86-9766 (RDEA119) is a potent and highly selective inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer Healthcare.
  • We are currently preparing for the commencement of Phase 3 studies of lesinurad which will focus on patients who do not reach target serum uric acid levels with, or are intolerant to, the current standard of care, allopurinol.  In anticipation of these studies, we recently initiated two observational studies i
    '/>"/>

  • SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Ardea Biosciences to Present at Upcoming Investor Conferences
    2. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
    3. Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
    4. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
    5. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
    6. Ardea Biosciences Prices Public Offering of Common Stock
    7. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    8. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    9. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    10. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    11. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
    (Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
    (Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
    (Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
    Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
    ... Immunosyn,Corporation (OTC Bulletin Board: IMYN), a biotechnology firm ... rights to,the biopharmaceutical SF-1019 from its affiliate Argyll ... ending March 31, 2008., For the quarter ... general and administrative expenses and $13,393.00 in interest ...
    ... 16 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... of InterMune, will present at the Citigroup 2008,Global Healthcare ... 1:30 p.m. EDT., To access a live audio ... log on to the investor relations page of InterMune,s,corporate ...
    ... May 16 StemCyte Inc. today announced,that Chief Scientific ... a focus on the StemCyte,s Indian joint venture at ... will present during the session on "Stem Cells - ... on Saturday, May 17. His,presentation will include information about ...
    Cached Biology Technology:Immunosyn Corporation Files 10-Q 2Immunosyn Corporation Files 10-Q 3StemCyte Chief Scientific Officer to Present Company Overview with Focus on Indian Joint Venture at TiEcon 2008 2
    (Date:7/9/2014)... one gene for another in a line of living ... reality within this decade. As with any new technology, ... disease-causing genes in humans, for example--as well as questions ... of those concerns to rest: using gene-editing techniques on ... in the cells. The new results were published July ...
    (Date:7/9/2014)... As climate change shifts the geographic ranges in which ... it has on their parasites. Does an increased range ... as well? , Not necessarily, says a team of ... Armand Kuris. In a study published in the ... that for some species, the opposite may happen: Hosts ...
    (Date:7/9/2014)... Fla. (July 9, 2014) Emerging fungal pathogens ... other parasitic group, causing population declines of amphibians, ... the University of South Florida published in the ... can acquire behavioral or immunological resistance to a ... declines. , "Acquired resistance is important because ...
    Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2
    ... are developing new technologies that combine a laser ... particles such as bacteria, viruses and DNA for ... to food safety. The technologies could bring ... or miniature instruments that perform measurements normally requiring ...
    ... have no way of predicting which threatened miscarriages will ... we are unable to target attempts to rescue the ... counselling," she said. "This has led to wasteful and ... hospital admissions for bed rest, sexual abstinence, low dose ...
    ... For the first time, fertility experts have shown that, ... poor oral health can have a significant effect on the ... meeting of the European Society of Human Reproduction and Embryology ... of the same order of magnitude as the effect of ...
    Cached Biology News:Laser, electric fields combined for new 'lab-on-chip' technologies 2Laser, electric fields combined for new 'lab-on-chip' technologies 3Researchers can predict accurately the outcome of pregnancies threatening to miscarry 2Gum disease can increase the time it takes to become pregnant 2Gum disease can increase the time it takes to become pregnant 3
    Collected from 8-12 week-old New Zealand or Californian rabbits.,Supplied in lyophilized form....
    Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
    5 minutes from gel band to purified DNA...
    ...
    Biology Products: